J Ethnopharmacol:归黄方治疗慢性前列腺炎的多靶点作用机制研究

2022-06-10 紫菀款冬 MedSci原创

检验和进一步阐明归黄方对慢性前列腺炎的多靶点治疗机制。

背景:慢性前列腺炎(CP)是一种复杂、难治且普遍存在的男性泌尿系统疾病,没有有效的治疗方法。归黄方(GHF)是中国医学科学院西苑医院几十年来使用的一种中药复方,遵循中医学的“君臣佐使”原则,“君药”是当归、黄柏,“臣药”是金银花、姜黄、乳香、没药、白芷,“佐使”是车前草,白花蛇舌草、陈皮。GHF具有治疗CP的优势,但其机制尚不清楚。研究和探索GHF的作用机制将有助于开发一种有潜在价值的CP药物,并对CP有更深入的了解。

目的:检验和进一步阐明GHF对CP的多靶点治疗机制。

材料和方法:使用UPLC-Q/TOF-MS鉴定GHF中的化学成分。GHF的活性成分和潜在靶点使用网络药理学和分子对接对治疗CP的药物进行筛选和分析。构建CP大鼠模型,以研究GHF对CP的治疗作用,并根据网络药理学的结果验证关键靶点和核心通路的影响。

结果:UPLC-Q/TOF-MS共鉴定出143种GHF成分,预测出111个CP-GHF潜在靶点。构建了“药物成分靶向途径”网络,符合“君臣佐使”原则。GHF显著降低前列腺指数,减轻前列腺组织学损伤,减少前列腺中CD3+T细胞和CD45+白细胞浸润,下调促炎细胞因子IL-1β、IL-6、IL-18、COX-2、MCP-1和TNF-α的表达,降低ROS水平,减轻MDA的产生,同时增加SOD和GSH-PX水平。同时,GHF抑制巨噬细胞凋亡,下调PI3K、AKT和P65 NF-κB的mRNA水平,抑制PI3K、AKT和P65 NF-κB的磷酸化。

结论:基于网络药理学和实验验证的策略被用于阐明GHF抗CP的潜在“多成分、多靶点和多途径”作用模式。证实了GHF可抑制氧化应激和炎症反应,抑制巨噬细胞凋亡,抑制CP大鼠炎症相关PI3K/AKT/NF-κB通路的激活。这些发现拓展了传统的“一种药物击中一个靶点”的观点,并为中药复方多靶点治疗机制的未来发现提供了新的见解和指示范例。

 

文献来源:

Liu S, Zhao F, Deng Y, et al. Investigating the multi-target therapeutic mechanism of Guihuang formula on Chronic Prostatitis [published online ahead of print, 2022 May 14]. J Ethnopharmacol. 2022;294:115386. doi:10.1016/j.jep.2022.115386

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1787801, encodeId=c6811e8780154, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Nov 09 08:48:18 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996481, encodeId=fc3919964817c, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Nov 03 22:48:18 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056231, encodeId=55e92056231dd, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Feb 23 21:48:18 CST 2023, time=2023-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788479, encodeId=f85b1e8847912, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Mar 17 10:48:18 CST 2023, time=2023-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721965, encodeId=8e6e1e21965f6, content=<a href='/topic/show?id=99474349903' target=_blank style='color:#2F92EE;'>#多靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43499, encryptionId=99474349903, topicName=多靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61333121812, createdName=zhangph, createdTime=Fri May 05 08:48:18 CST 2023, time=2023-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908710, encodeId=b0881908e109c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed May 03 22:48:18 CST 2023, time=2023-05-03, status=1, ipAttribution=)]
    2022-11-09 jj000001
  2. [GetPortalCommentsPageByObjectIdResponse(id=1787801, encodeId=c6811e8780154, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Nov 09 08:48:18 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996481, encodeId=fc3919964817c, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Nov 03 22:48:18 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056231, encodeId=55e92056231dd, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Feb 23 21:48:18 CST 2023, time=2023-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788479, encodeId=f85b1e8847912, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Mar 17 10:48:18 CST 2023, time=2023-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721965, encodeId=8e6e1e21965f6, content=<a href='/topic/show?id=99474349903' target=_blank style='color:#2F92EE;'>#多靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43499, encryptionId=99474349903, topicName=多靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61333121812, createdName=zhangph, createdTime=Fri May 05 08:48:18 CST 2023, time=2023-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908710, encodeId=b0881908e109c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed May 03 22:48:18 CST 2023, time=2023-05-03, status=1, ipAttribution=)]
    2022-11-03 yb6560
  3. [GetPortalCommentsPageByObjectIdResponse(id=1787801, encodeId=c6811e8780154, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Nov 09 08:48:18 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996481, encodeId=fc3919964817c, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Nov 03 22:48:18 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056231, encodeId=55e92056231dd, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Feb 23 21:48:18 CST 2023, time=2023-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788479, encodeId=f85b1e8847912, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Mar 17 10:48:18 CST 2023, time=2023-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721965, encodeId=8e6e1e21965f6, content=<a href='/topic/show?id=99474349903' target=_blank style='color:#2F92EE;'>#多靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43499, encryptionId=99474349903, topicName=多靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61333121812, createdName=zhangph, createdTime=Fri May 05 08:48:18 CST 2023, time=2023-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908710, encodeId=b0881908e109c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed May 03 22:48:18 CST 2023, time=2023-05-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1787801, encodeId=c6811e8780154, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Nov 09 08:48:18 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996481, encodeId=fc3919964817c, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Nov 03 22:48:18 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056231, encodeId=55e92056231dd, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Feb 23 21:48:18 CST 2023, time=2023-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788479, encodeId=f85b1e8847912, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Mar 17 10:48:18 CST 2023, time=2023-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721965, encodeId=8e6e1e21965f6, content=<a href='/topic/show?id=99474349903' target=_blank style='color:#2F92EE;'>#多靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43499, encryptionId=99474349903, topicName=多靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61333121812, createdName=zhangph, createdTime=Fri May 05 08:48:18 CST 2023, time=2023-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908710, encodeId=b0881908e109c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed May 03 22:48:18 CST 2023, time=2023-05-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1787801, encodeId=c6811e8780154, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Nov 09 08:48:18 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996481, encodeId=fc3919964817c, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Nov 03 22:48:18 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056231, encodeId=55e92056231dd, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Feb 23 21:48:18 CST 2023, time=2023-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788479, encodeId=f85b1e8847912, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Mar 17 10:48:18 CST 2023, time=2023-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721965, encodeId=8e6e1e21965f6, content=<a href='/topic/show?id=99474349903' target=_blank style='color:#2F92EE;'>#多靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43499, encryptionId=99474349903, topicName=多靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61333121812, createdName=zhangph, createdTime=Fri May 05 08:48:18 CST 2023, time=2023-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908710, encodeId=b0881908e109c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed May 03 22:48:18 CST 2023, time=2023-05-03, status=1, ipAttribution=)]
    2023-05-05 zhangph
  6. [GetPortalCommentsPageByObjectIdResponse(id=1787801, encodeId=c6811e8780154, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Nov 09 08:48:18 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996481, encodeId=fc3919964817c, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Nov 03 22:48:18 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056231, encodeId=55e92056231dd, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Feb 23 21:48:18 CST 2023, time=2023-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788479, encodeId=f85b1e8847912, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Mar 17 10:48:18 CST 2023, time=2023-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721965, encodeId=8e6e1e21965f6, content=<a href='/topic/show?id=99474349903' target=_blank style='color:#2F92EE;'>#多靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43499, encryptionId=99474349903, topicName=多靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61333121812, createdName=zhangph, createdTime=Fri May 05 08:48:18 CST 2023, time=2023-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908710, encodeId=b0881908e109c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed May 03 22:48:18 CST 2023, time=2023-05-03, status=1, ipAttribution=)]

相关威廉亚洲官网

慢性前列腺炎中西医结合诊疗威廉亚洲博彩公司 (试行版)

慢性前列腺炎中西医结合诊疗威廉亚洲博彩公司 (试行版).pdf